Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?

Petr Kujal, Věra Čertíková Chábová, Zdenka Vernerová, Agnieszka Walkowska, Elzbieta Kompanowska-Jezierska, Janusz Sadowski, Zdeňka Vaňourková, Zuzana Husková, Martin Opočenský, Petra Škaroupková, Stanislava Schejbalová, Herbert J Kramer, Dan...

. 2010 ; 37 (12) : 1159-1169.

Language English Country Australia

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12026769

Grant support
NS10500 MZ0 CEP Register
NS9703 MZ0 CEP Register
NS10499 MZ0 CEP Register

1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprotective actions beyond their blood pressure (BP)-lowering effects. 2. Because this notion has recently been questioned, in the present study we compared the effects of a RAS-dependent antihypertensive therapy (a combination of trandolapril, an angiotensin-converting enzyme inhibitor (ACEI) and losartan, an angiotensin-II (AngII) receptor subtype 1A receptor antagonist) with a 'RAS-independent' antihypertensive therapy (a combination of labetalol, an alfa- and beta-adrenoreceptor antagonist with the diuretics, hydrochlorothiazide and furosemide) on the progression of CKD after 5/6 renal ablation (5/6 NX) in Ren-2 renin transgenic rats (TGR), a model of AngII-dependent hypertension. Normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats after 5/6 NX served as controls. 3. RAS-dependent and -independent antihypertensive therapies normalized BP and survival rate, and prevented the development of cardiac hypertrophy and glomerulosclerosis to the same degree in 5/6 NX HanSD rats and in 5/6 NX TGR. The present findings show that renoprotection, at least in rats after 5/6 NX, is predominantly BP-dependent. When equal lowering of BP was achieved, leading to normotension, cardio- and renoprotective effects were equivalent irrespective of the type of antihypertensive therapy. 4. These findings should be taken into consideration in attempts to develop new therapeutic approaches and strategies aimed to prevent the progression of CKD and to lower the incidence of ESRD.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026769
003      
CZ-PrNML
005      
20220531082823.0
007      
ta
008      
120816s2010 at f 000 0#eng||
009      
AR
024    7_
$a 10.1111/j.1440-1681.2010.05453.x $2 doi
035    __
$a (PubMed)20880190
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Kujal, Petr $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $7 xx0244311
245    10
$a Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? / $c Petr Kujal, Věra Čertíková Chábová, Zdenka Vernerová, Agnieszka Walkowska, Elzbieta Kompanowska-Jezierska, Janusz Sadowski, Zdeňka Vaňourková, Zuzana Husková, Martin Opočenský, Petra Škaroupková, Stanislava Schejbalová, Herbert J Kramer, Dan Rakušan, Jan Malý, Ivan Netuka, Ivana Vaněčková, Libor Kopkan, Luděk Červenka
520    9_
$a 1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprotective actions beyond their blood pressure (BP)-lowering effects. 2. Because this notion has recently been questioned, in the present study we compared the effects of a RAS-dependent antihypertensive therapy (a combination of trandolapril, an angiotensin-converting enzyme inhibitor (ACEI) and losartan, an angiotensin-II (AngII) receptor subtype 1A receptor antagonist) with a 'RAS-independent' antihypertensive therapy (a combination of labetalol, an alfa- and beta-adrenoreceptor antagonist with the diuretics, hydrochlorothiazide and furosemide) on the progression of CKD after 5/6 renal ablation (5/6 NX) in Ren-2 renin transgenic rats (TGR), a model of AngII-dependent hypertension. Normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats after 5/6 NX served as controls. 3. RAS-dependent and -independent antihypertensive therapies normalized BP and survival rate, and prevented the development of cardiac hypertrophy and glomerulosclerosis to the same degree in 5/6 NX HanSD rats and in 5/6 NX TGR. The present findings show that renoprotection, at least in rats after 5/6 NX, is predominantly BP-dependent. When equal lowering of BP was achieved, leading to normotension, cardio- and renoprotective effects were equivalent irrespective of the type of antihypertensive therapy. 4. These findings should be taken into consideration in attempts to develop new therapeutic approaches and strategies aimed to prevent the progression of CKD and to lower the incidence of ESRD.
650    _2
$a aldosteron $x moč $7 D000450
650    _2
$a angiotensin II $x krev $x metabolismus $7 D000804
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakologie $7 D047228
650    _2
$a inhibitory ACE $x farmakologie $7 D000806
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x farmakologie $7 D000959
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a kardiomegalie $x farmakoterapie $x prevence a kontrola $7 D006332
650    _2
$a chymosin $x metabolismus $7 D012085
650    _2
$a kreatinin $x krev $x metabolismus $x moč $7 D003404
650    _2
$a diabetické nefropatie $x farmakoterapie $x prevence a kontrola $7 D003928
650    _2
$a diuretika $x farmakologie $7 D004232
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a furosemid $x farmakologie $7 D005665
650    _2
$a hydrochlorthiazid $x farmakologie $7 D006852
650    _2
$a hypertenze $x farmakoterapie $x metabolismus $7 D006973
650    _2
$a indoly $x farmakologie $7 D007211
650    _2
$a chronické selhání ledvin $x farmakoterapie $x metabolismus $x prevence a kontrola $7 D007676
650    _2
$a labetalol $x farmakologie $7 D007741
650    _2
$a losartan $x farmakologie $7 D019808
650    _2
$a proteinurie $x krev $x metabolismus $x moč $7 D011507
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a potkani transgenní $7 D055647
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Čertíková-Chábová, Věra $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic; Laboratory of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland $7 xx0095872
700    1_
$a Vernerová, Zdenka, $u Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic $d 1960-2020 $7 jo2002104672
700    1_
$a Walkowska, A. $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $7 _AN077977
700    1_
$a Kompanowska-Jezierska, Elżbieta, $d 1959- $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0273376
700    1_
$a Sadowski, Janusz, $d 1937- $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0227641
700    1_
$a Vaňourková, Zdeňka, $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $d 1973- $7 xx0074217
700    1_
$a Husková, Zuzana, $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $d 1978- $7 xx0074206
700    1_
$a Opočenský, Martin $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 _AN045104
700    1_
$a Škaroupková, Petra $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0117683
700    1_
$a Schejbalová, Stanislava $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kramer, Herbert J. $u Section of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany $7 xx0085908
700    1_
$a Rakušan, Dan $7 xx0219012 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic
700    1_
$a Malý, Jan, $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $d 1943-2021 $7 nlk19990073523
700    1_
$a Netuka, Ivan, $u Center for Cardiovascular Research, Prague, Czech Republic $d 1973- $7 xx0074183
700    1_
$a Vaněčková, Ivana, $u Center for Cardiovascular Research, Prague, Czech Republic $d 1964- $7 xx0030586
700    1_
$a Kopkan, Libor $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $7 xx0107287
700    1_
$a Červenka, Luděk, $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Physiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $d 1967- $7 xx0037105
773    0_
$w MED00007158 $t Clinical and experimental pharmacology & physiology $x 1440-1681 $g Roč. 37, č. 12 (2010), s. 1159-1169
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20880190 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20220531082819 $b ABA008
999    __
$a ok $b bmc $g 948811 $s 784115
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 37 $c 12 $d 1159-1169 $i 1440-1681 $m Clinical and experimental pharmacology & physiology $n Clin Exp Pharmacol Physiol $x MED00007158
GRA    __
$a NS10500 $p MZ0
GRA    __
$a NS9703 $p MZ0
GRA    __
$a NS10499 $p MZ0
LZP    __
$b NLK113 $a Pubmed-20120816/11/01
Back

Find record

Citation metrics

Archiving options